Our Maternal Health Trials
Tranexamic acid for the treatment of postpartum haemorrhage: An international, randomised, double blind, placebo controlled trial. The WOMAN trial showed that if given within 3 hours, TXA can reduce the risk of death due to bleeding by one third
Sub-Studies
- WOMAN-ETAC: Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage
- ETAPLaT: Effects of tranexamic acid on platelet function and thrombin generation (ETAPlaT): WOMAN trial sub-study.
WOMAN-2 Trial (on-going)
Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: an international, randomised, double-blind, placebo controlled trial
Pharmaco - TXA Trial (completed)
Phase 1 trial in healthy volunteers aimed at determining the bioavailability and pharmacokinetics of TXA following administration of TXA by different routes and relevant doses
Publication: Physiologically based modeling of tranexamic acid pharmacokinetics following intravenous, intramuscular, subcutaneous, and oral administration in healthy volunteers (view PDF)
WOMAN Pharmaco - TXA Trial (on-going)
WOMAN-PharmacoTXA trial will assess the pharmacokinetics and pharmacodynamics of tranexamic acid administered by intravenous (IV), intramuscular (IM) or oral liquid routes in women giving birth by caesarean section with at least one risk factor for PPH
Are you interested in collaborating on one of our ongoing trials? Email enquiries to lshtmctu@lshtm.ac.uk
Our Funders
